Clinical trial · Observational
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
Correlation Between Epithelial Growth Factor Receptor(EGFR) Mutation Using cfDNA and CTCs in Patients With Non-Small Cell Lung Cancer
NCT02422628CI-TRIAL-00025143unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Correlation of epithelial growth factor receptor mutation in blood of lung cancer patient and clinical outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- EGFR mutation postive
- description
- Blood samples every 3 months till disease progression or intolerable due to side effect.
- label
- EGFR mutation wild type
- description
- Blood samples before treatment once.
- label
- Healthy Volunteers
- description
- Blood samples once.
Primary outcomes (1)
- measure
- Progressive disease measured by RECIST criteria after receiving 1st line EGFR-TKI
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 85 Years
Show eligibility criteria text
NSCLC patients should fulfill the following criteria: 1. Provision of informed consent prior to any study specific procedures 2. Patients with non-small cell lung cancer, adenocarcinoma, aged 20 years and older. 3. Tumor harboring EGFR mutation including activating mutation L858R, Del19 or/and resistant mutation T790M, or/and rare mutation G719, S768, L861 4. Treatment naive 5. Patients will receive EGFR-TKI as first line treatment. For inclusion in the study of control subjects (100 volunteers), they should fulfill the following criteria: 1. Provision of informed consent prior to any study specific procedures 2. Patients aged 20 years and older 3. Volunteers without any lung cancer related diagnosis or symptoms 4. EGFR TKI treatment naïve and without any EGFR TKI treatment in the following process For inclusion in the study of control subjects (100 EGFR wild-type), they should fulfill the following criteria: 1. Provision of informed consent prior to any study specific procedures 2. Patients with non-small cell lung cancer, adenocarcinoma, aged 20 years and older. 3. Tumor with no EGFR mutation detected (mutation L858R, Del19 or/and resistant mutation T790M, or/and rare mutation G719, S768, L861) 4. EGFR TKI treatment naïve and without any EGFR TKI treatment in the following process \------- Exclusion criteria For exclusion in the study of NSCLC patients and control subjects should fulfill the following criteria: 1. Subjects should not enter the study if any of the following exclusion criteria are fulfilled: Involvement in the planning and/or conduct of the study (applies to staff at the study site) 2. Previous enrolment in the present study 3. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease) 4. Evidence of any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study 5. Pregnancy or breast-feeding
References
Publications (0)
Data not yet available
No reference posted for this study.